. 2023 Apr 12;16:1271–1278. doi: 10.2147/IJGM.S403316

Table 1.

Analysis of Baseline Characteristics of Patients

Patient Characteristics		n	Median PFS	P	Median OS	P
Age	≤50 years old	6	6	0.654	21	0.721
Age	>50 years old	15	13	0.654	21	0.721
Sex	Male	19	10	0.396	20	0.488
Sex	Female	2	5	0.396	15	0.488
Child-Pugh class	A	14	12	0.012	21	0.003
	B	5	9		8
	C	2	2		-
Tumor thrombus	Yes	5	3	0.003	24	0.598
Tumor thrombus	None	16	12	0.003	21	0.598
KPS	>70	11	13	0.028	28	0.001
KPS	60–70	10	3	0.028	13	0.001
Liver cirrhosis	Yes	14	8	0.153	20	0.2
Liver cirrhosis	No	7	12	0.153	24	0.2
Combination therapy	Yes	14	10	0.298	24	0.038
Combination therapy	No	7	6	0.298	20	0.038
Metastatic site	Lung	10	6	0.149	13	0.194
	Mediastinal/supraclavicular	3	6		-
	Brain	1	17		-
	Adrenal gland	2	3		-
	Bone	5	13		8
Radiotherapy dose	≤52Gy	8	6	0.007	13	0.038
Radiotherapy dose	>52Gy	13	12	0.007	21	0.038
Failure mode	Intrahepatic	9	9	0.533	14	0.032
Failure mode	Extrahepatic	9	10	0.533	28	0.032
Ascites	Yes	7	3	0.001	13	0.001
Ascites	None	14	12	0.001	24	0.001

Abbreviations: PFS, progression-free survival; OS, overall survival; KPS, Karnofsky performance status; CIK, cytokine-induced killer.